Authors

Latest:

The Landscape of Chemoprevention in Lung Cancer: A Conversation With Waun K. Hong, MD, PhD

Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.

Charles Catton, MD

Latest:

Dr. Catton on Quality Assurance for Radiation Therapy for Sarcoma

Charles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.

Charles Coombes, MD

Latest:

Dr. Coombes on Intriguing Results With Celecoxib in Breast Cancer

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

Charles D. Blanke, MD, OHSU

Charles E. Argoff, MD, Albany Medical Center

Charles E. Geyer Jr, MD

Latest:

Dr Geyer on the Efficacy of Perioperative Atezolizumab Plus Chemotherapy in Stage II/III TNBC

Charles E. Geyer, Jr., MD, discusses the efficacy and safety of perioperative atezolizumab plus chemotherapy in stage II/III triple-negative breast cancer.

Charles G. Drake, MD, PhD

Latest:

Dr. Drake on the Role of Cytoreductive Nephrectomy in RCC

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.

Charles G. Mullighan, MBBS, MSc, MD

Latest:

Dr. Mullighan on Germline Predisposition to ALL

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Charles Gourley, PhD, MBChB

Latest:

Benefit of Maintenance Olaparib in Patients With Ovarian Cancer

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.

Charles J. Link, Jr, MD

Latest:

Dr. Link on Algenpantucel-L for Pancreatic Cancer

Charles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.

Charles J. Ryan, MD

Latest:

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Charles J. Ryan, MD, UCSF

Charles J. Ryan, MD, UCSF Helen Diller Comprehensive Cancer Center

Charles J. Ryan, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Charles L. Loprinzi, MD, Mayo Clinic

Charles L. Sawyers, MD

Latest:

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Charles L. Shapiro, MD

Latest:

Dr. Shapiro on Preventative Drugs in Breast Cancer

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Charles Loprinzi, MD, Mayo Clinic Rochester

Charles M. Farber, MD, PhD

Latest:

The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies

Rituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies

Charles M. Perou, PhD

Latest:

Charles Perou on Biomarker Assay Use in ASCO Breast Cancer Guideline

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.